National Class 1 Biological New Drug Eponemin for Injection (Shaite®) has been approved for marketing on November 1, 2023. As the world's first approved DR4/DR5 agonist, its marketing marks a big step forward in the field of multiple myeloma treatment in China. Sponsored by Chengdu High-Tech Medical Association, the online case seminar on Eponemin for Injection was held in Chengdu on July 22, 2024, hoping to help experts better apply this new domestic original biological drug and bring new hope to patients.

Translated with DeepL.com (free version)